25 May 2013
Keywords: novartis, tasigna, gets, eu, approval, swiss, drug
Article | 03 December 2007
Swiss drug major Novartis says that Tasigna (nilotinib) has received
European Union approval as a new anticancer therapy for patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 December 2007
24 May 2013
© 2013 thepharmaletter.com